Agenus Inc.
Agenus Inc. (AGEN) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · AGEN · as of Jun 9, 2026
Key Statistics
Explore Agenus Inc. Data
agen stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 11 · Buy rate: 72.7%
The AGEN analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month price target is $7.33, representing +133.44% upside from the current price of $3.14.
Competitors & Peers
agen competitorsAGEN
ABOS
FATE
HURA
INO
IRDStock Performance
Full HistoryAbout Agenus Inc.
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes …
what is agenus inc. · agen stock overview · agenus inc. company profile · who is agenus inc. ceo · agen NASDAQ · agenus inc. headquarters · agenus inc. business segments
About Stock Overview & Key Data
Agenus Inc. (AGEN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Feb 8, 2000. As of the latest trading session, AGEN stock price is $3.14, with a market capitalization of $130.8M. The stock has returned -43.42% over the past 12 months and +0.00% year-to-date.
According to 11 Wall Street analysts, the consensus rating for Agenus Inc. stock is Buy, with an average 12-month price target of $7.33. In fiscal year 2025, Agenus Inc. reported revenue of $114.2M and net income of $115000.00. For detailed data — including Agenus Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Agenus Inc. (AGEN) stock price is $3.14. The stock is traded on NASDAQ under the ticker symbol AGEN. The 52-week range is $2.71 – $7.34.